Fierce Biotech May 6, 2024
Italian pharma Chiesi is betting almost $500 million on Gossamer Bio’s pulmonary arterial hypertension (PAH) candidate.
The two will partner on global commercialization efforts for seralutinib, according to an announcement Monday, with Gossamer receiving $160 million in R&D reimbursements and $326 million biobucks up for grabs. Gossamer is currently enrolling a phase 3 seralutinib study for patients with PAH, the same indication that Merck recently won FDA approval for with Winrevair.
Gossamer will continue to spearhead development efforts and pay for the ongoing phase 3 study, with both companies sharing future trial costs. The smaller biotech will also lead U.S. commercialization efforts for PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD), though both companies will share costs....
Today's Sponsors
Today's Sponsor